TLRY climbs over 4% after expansion of medical cannabis production and HelloMD acquisition

Traders Union
All News
Stocks
Tilray surges 4.26% today on expansion

Highlights

Tilray is expanding medical cannabis production capacity to approximately 275 metric tonnes by growing its Quebec and Portugal operations.
The company is targeting EU-GMP certification for its Quebec facility within 12 months and has acquired HelloMD Corporation to support patient access infrastructure.
Tilray stock trades near the session high at $4.87 with mixed momentum indicators and an expected 5-day range of $4.63 to $5.11.

Production boost and acquisitions as firm targets international demand surge

Tilray announced a significant expansion of its medical cannabis cultivation operations, increasing total annual production capacity to approximately 275 metric tonnes by expanding its Quebec site and EU-GMP-certified facility in Portugal. The company is responding to rising international demand, particularly in Europe and regulated markets, and aims to achieve EU-GMP certification for its Quebec facility within 12 months. Tilray also acquired HelloMD Corporation to enhance patient-access infrastructure in medical cannabis markets.

Anton Kharitonov, expert at Traders Union, sees the rally in Tilray as primarily driven by hype following the medical cannabis expansion news. He remains skeptical given the persistent cap below the $7.05 200-day moving average. While the acquisition of HelloMD and facility upgrades attract attention, the company's long-term momentum is still bearish. Mixed momentum signals and high intraday volatility reveal unstable sentiment. "Traders should remain cautious as the longer-term technical weakness and divergent signals point to increased downside risk if support at $4.63 fails."

Viktoras Karapetjanc, expert at Traders Union, highlights strong fundamental progress as Tilray expands capacity and pursues EU-GMP certification. He sees increased production and the HelloMD acquisition as major strategic moves for international demand capture. The baseline scenario favors ongoing consolidation with upside potential. "With new markets opening and bullish structure reinforced by global expansion, I expect further growth if buyers sustain pressure above $5.11 in the coming sessions."

Jainam Mehta, market strategist, notes price action above the 20-day and 50-day averages but emphasizes resistance at $5.11 and the capped long-term trend. He observes that divergence in short-term indicators may trigger tactical opportunities for nimble traders. Intraday volatility remains elevated, favoring quick, scenario-based trades. "Given current momentum splits, I see merit in watching for a breakout above $5.11 or fade attempts if price stalls near resistance."

Near-term strength and mixed signals as price nears resistance

Tilray is trading above both its 20-day and 50-day moving averages ($4.45 and $4.5), but remains below the 200-day moving average at $7.05. This setup indicates near-term and intermediate strength, with longer-term momentum still on the bearish side. The nearest support is identified at the recent week high of $4.86, while resistance stands at the forecast band top of $5.11. Momentum indicators are mixed: the MACD and RSI are signaling Buy, the ADX is Neutral, and the Stochastic RSI points to Strong Sell, suggesting divergence among short-term signals. CCI and BBP favor the buyers, with BBP reflecting buyer dominance intraday. Price is near session highs with intraday volatility at 4.61%, confirming persistent strength despite mixed momentum signals.

Earlier, analysts noted that Tilray was consolidating within a defined range, lacking clear signals for a decisive breakout. The latest expansion and upward move in the stock adds a fresh catalyst, making the $5.11 resistance a critical level to watch for potential upside in the near term.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.